Collins, King Join Bipartisan Effort in Urging Action to Address Practices of Pharmaceutical Companies Undermining 340B Program

WASHINGTON, D.C. – U.S. Senators Susan Collins (R-Maine) and Angus King (I-Maine) joined a bipartisan group of their colleagues in calling for enforcement action to address practices of pharmaceutical companies that threaten to undermine the 340B Drug Pricing Program during the COVID-19 public health emergency. In their letter to Health and Human Services (HHS) Secretary Alex Azar, the Senators urge the administration to take immediate enforcement action to halt these tactics and ensure safety-net providers are able to continue providing life-saving medications to patients across the country.

 

The 340B program requires drug companies to sell discounted prescription drugs to safety net hospitals, rural health facilities, and other entities that provide care in underserved communities. Savings from the 340B program ensure that these “covered entities” are able to continue to serve their patients. However, drug manufacturers have recently announced new burdensome requirements on covered entities beyond the scope of the 340B program, or they have announced that they will no longer provide discounts for medications shipped to pharmacies that dispense drugs to patients on behalf of covered entities.

 

The Senators write, “In the midst of the ongoing COVID-19 pandemic, where providers have seen drops in revenue and available resources, it is critically important that 340B covered entities, including federally qualified health centers (FQHCs), FQHC Look-Alikes, children’s hospitals, Ryan White HIV/AIDS clinics, and other safety-net hospitals and providers are able to continue to serve the individuals who seek out their care. As these threats to the Program progress, we fear the potential exacerbation of these shortfalls in resources for providers at a time when they are needed most.”

 

“Maine's health centers are community-based and governed by local people,” said Darcy Shargo, CEO of the Maine Primary Care Association. “We are very proud of how carefully and thoughtfully they have used 340B funds to improve the lives of people in their communities, such as expanding low cost drug programs, expanded substance use disorder treatment programs, dental programs and more. The loss of this program would be devastating, not just to the community health centers but more importantly to the people they serve.”

 

“The 340B Program provides the necessary resources to support critical programs for low-income patients throughout our service area – and at no cost to tax payers,” said Brian Marden, Chief Pharmacy Officer for MaineHealth. “We join Maine’s senators in asking the Secretary to intervene in recent pharmaceutical company action that undermine this program which has become a lifeline for vulnerable patients.”

 

“The 340B program is critical in helping Northern Light Health participating hospitals to stretch scarce federal resources as far as possible, providing comprehensive healthcare services in vulnerable communities across the State of Maine,” said Lisa Harvey-McPherson, RN, Vice President of Government Relations at Northern Light Health. “As our hospitals, and communities that we serve, recover from the negative financial impact of COVID, it is more important than ever that pharmaceutical manufacturers follow the law to ensure that discounts continue for medications shipped to Northern Light Health contract pharmacies providing necessary medications to our patients.  We thank Senator Collins and Senator King for their leadership to address this critical issue.”

 

The bipartisan letter was also signed by Senators Tammy Baldwin (R-Wis.), Rob Portman (R-Ohio), Debbie Stabenow (D-Mich.), Shelley Moore Capito (R-W. Va.), John Thune (R-S.D.), Ben Cardin (D-Md.), Patty Murray (D-Wash.), Ron Wyden (D-Ore.), Jerry Moran (R-Kansas), Jon Tester (D-Mont.), Mike Rounds (R-S.D.), Doug Jones (D-Ala.), Joni Ernst (R-Iowa), Gary Peters (D-Mich.), John Boozman (R-Ark.), Bob Casey (D-Penn.), Cindy Hyde-Smith (R-Miss.), Mark Warner (D-Va.), Roger Wicker (R-Miss.), Kevin Cramer (R-N.D.), Chuck Schumer (D-N.Y.), Thom Tillis (R-N.C.), Chris Van Hollen (D-Md.), Elizabeth Warren (D-Mass.), Sherrod Brown (D-Ohio.), and Kirsten Gillibrand (D-N.Y.). 

 

The full letter is available HERE and below.

 

+++

 

 

Dear Secretary Azar:

 

We write to express our concerns regarding recent actions from pharmaceutical manufacturers that threaten to undermine the role of contract pharmacies in the 340B Drug Pricing Program. In the midst of the ongoing COVID-19 pandemic, where providers have seen drops in revenue and available resources, it is critically important that 340B covered entities, including federally qualified health centers (FQHCs), FQHC Look-Alikes, children’s hospitals, Ryan White HIV/AIDS clinics, and other safety-net hospitals and providers are able to continue to serve the individuals who seek out their care. As these threats to the Program progress, we fear the potential exacerbation of these shortfalls in resources for providers at a time when they are needed most. While we understand that the Health Resources and Services Administration (HRSA) is further investigating these actions, we urge HRSA to take immediate and appropriate enforcement action to halt these tactics and ensure safety-net providers are able to continue providing life-saving medications to patients across the country.

 

As you are aware, on September 1, 2020, Eli Lilly announced that the company would no longer allow 340B covered entities to receive discounts for products that are shipped to a contract pharmacy, with an exception for insulin. This follows similar actions from AstraZeneca, which announced in August that it would refuse 340B pricing to hospitals with on-site pharmacies for any drugs dispensed through contract pharmacies. Similarly, other companies have imposed additional and burdensome reporting requirements on all contract pharmacy claims.  For covered entities, and in particular rural hospitals and other rural covered entities that rely disproportionately on contract pharmacies, these changes could have long-lasting repercussions that will challenge a covered entity’s ability to support its community now during this pandemic and in the future.

 

The Public Health Service Act requires that manufacturers wishing to participate in Medicaid and Medicare Part B enter into agreements with the Department of Health and Human Services (HHS) that “require that the manufacturer offer each covered entity covered outpatient drugs for purchase at or below the applicable ceiling price if such drug is made available to any other purchaser at any price.” Further, HRSA has recognized the importance of contract pharmacies by acknowledging such arrangements in current guidance. We believe these recent actions by pharmaceutical manufacturers run counter to the statute and create a dangerous and negative precedent for the 340B Program and the providers and patients it serves.

 

To ensure pharmaceutical manufacturers continue to comply with the 340B statute and provide discounts to safety-net providers, we call on HRSA to take appropriate, prompt enforcement action to address violations of the Public Health Service Act. We appreciate your attention to this important issue and look forward to partnering with you and stakeholders to ensure the 340B program continues to support access to quality health services with proper oversight and transparency.

 

###